Poxel S.A. - Special Call Transcript
Welcome to the Poxel KOL Investor Event Conference Call. My name is John, and I'll be your operator for today's call. (Operator Instructions)
And I will now turn the call over to Thomas Kuhn, CEO of Poxel. Thomas, you may begin.
Thank you. Hello, everyone. Thank you for joining us today. And I'm Thomas Kuhn, the CEO of Poxel. And alongside me is David Moller, Executive Vice President and Chief Scientific Officer of Poxel.
The event today will feature presentations from Poxel and 2 NASH key opinion leaders: Dr. Kenneth Cusi, Chief of Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the University of Florida; and Dr. Stephen Harrison, the Director of Summit Clinical Research. Thank you again, Ken and Stephen, for your -- for taking your precious time to be with us and to discuss our NASH pipeline.
The webcast today will cover detailed results from the Phase IIa STAMP-NAFLD study of PXL770 for the treatment of NASH, with a specific focus on the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |